More recently, melittin has also been identified as a modulator of the lipid metabolism in ovarian cancer cells, where it inhibits the nuclear translocation of sterol regulatory element-binding protein 1 (SREBP1) and reduces the SREBP1-driven transcription of fatty acid synthase, thereby suppressing lipogenesis and cell growth [78]. Here, SREBF1 is linked to ovarian cancer.